products

products

Our product pipeline

Camurus' development projects address serious unmet medical needs over a range of therapeutic areas, including cancer, endocrinology, pain, metabolic disease and drug addiction. Our product pipeline represents a mix of in-house and partnered projects in different development phases.

CAM2038 q1w
Opioid dependence
20%
CAM2038 q4w
Opioid dependence
20%
CAM2038 q1w
Chronic pain
20%
CAM2038 q4w
Chronic pain
20%
CAM2029
Neuroendocrine tumors
20%
CAM2029
Acromegaly
20%
CAM2032
Prostate cancer
20%
CAM4071
Undisclosed indication
20%
CAM2047
CINV
20%
CAM2048
Postoperative pain
20%
CAM2058
Postoperative pain & PONV
20%
CAM4072
Genetic Obesity
20%
CAM2043
Pulmonary Arterial Hypertension
20%
episil®
Oral mucositis
20%

CAM2029 growth hormone disorders

CAM2029 growth hormone disorders

CAM2029 growth hormone disorders

The product is developed by Novartis with support from Camurus for treatment of acromegaly and neuroendocrine tumours and has several important advantages over current marketed products. CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus' proprietary FluidCrystal® injection depot technology.

CAM2029 comprises the active substance octreotide, which is a synthetic peptide analogue of the endogenous peptide hormon somatostatin. Somatostatin analogues (SSA) are today standard in the safe and effective symptomatic treatment of patients with acromegaly and neuroendocrine tumors (NETs). SSAs have in clinical trials demonstrated efficacy against tumors and is a treatment option for unresectable NETs. Current marketed SSA products include short acting octreotide (Sandostatin® from Novartis and generic versions), the market leading formulation octreotide LAR (Sandostatin® LAR® from Novartis), and two long-acting formulations of lanreotide (Somatuline® LA® and Somatuline® Autogel® from Ipsen).

CAM2029 is provided in a prefilled syringe equipped with a needle stick protection device. The product is conveniently administered subcutaneously , also by the patient itself, without any complicated reconstitution steps or conditioning requirements before use. Moreover, CAM2029 is compatible with autorinjector devices, which may further facilitate patient self-administration.

CAM2029 key properties

  • Simple and convenient administration by prefilled syringe
  • Thin needle and small injection volume
  • Adapted for self-administration
  • High bioavailability
  • Manufacturing by standard processes




CAM2038 opioid dependence

CAM2038 opioid dependence

CAM2038 opioid dependence

CAM2038 includes two long-acting subcutaneous buprenorphine products for maintenance treatment of opiod dependence, intended for administration once weekly (q1w) and once monthly (q4w). The products, based on Camurus' proprietary FluidCrystal® injection depot technology, are being developed to address several shortcomings of currently available drugs, for instance poor compliance, extensive misuse and diversion, and frequent relapse to abuse.

CAM2038 combines the known and well documented active substance buprenorphine with Camurus' proprietary FluidCrystal® injection depot technology. Because of the long-acting effect, CAM2038 needs to be administered only 12 or 52 times per year, which reduces the burden of daily administration as is the case with current medications (often health care personnel monitored administration, which is time consuming and costly for patients and society). CAM2038 will be administered in a controlled setting by healtcare personnel as a convenient subcutaneous injection, which cannot be misused, abused, or diverted to the illegal market.

CAM2038 will be available in several doses for weekly and monthly administration. This flexibility was developed to enable the product to be used during all phases of opioid addiction treatment, from treatment induction to stabilization and long-term maintenance therapy. The dose flexibility is also important to meet the patients' individual needs, depending on treatment phase, abuse history, and other factors. CAM2038 will be provided in prefilled syringes with a needle stick protection device. The products are small volume subcutaneous injections without need for reconstitution before use.

CAM2038 key properties

  • Reduced dosing frequency
  • Protection against misuse, abuse, and diversion
  • No risk of pediatric exposure
  • Flexible doses for individualized treatment
  • Blockage of illegal opioids



CAM2038 chronic pain

CAM2038 chronic pain

CAM2038 chronic pain

CAM2038 is a subcutaneous injection depot of buprenorphine for simple and safe administration by a prefilled syringe. Besides treatment of opiod dependence, CAM2038 once weekly (q1w) and once monthly (q4w) are developed for treatment of chronic pain. Initially, the products will be used to treat opioid experienced patients, but product variants for opioid naive patients are also being developed.

CAM2038 gives a fast onset of effect and a dose proportional extended exposure without the same risk for overdose and respiratory depression which is associated with full mu agonists such as morphine, fentanyl, etc. The product profile corresponds well with the target profile for chronic pain drug products and addresses a clear medical need to combine pain relief with a reduced risk of misuse and improved safety. The subcutaneous route of administration is expected to increase compliance and reduce the risks of incorrect use. Also when compared with transdermal opioid formulations, it's indicating that CAM2038 may be particularly well suited for chronic pain patients with a history of misuse. While chronic pain and substance abuse disorders often occur concurrently, these patients are particularly difficult to treat using existing opioid products.

CAM2038 key properties

  • Reduced administration frequency
  • Reduced risk of misuse and diversion
  • Improved treatment compliance


CAM2032 prostate cancer

CAM2032 prostate cancer

CAM2032 prostate cancer

Camurus' CAM2032 is a long-acting formulation of leuprolide which features both fast onset and prolonged release of leuprolide acetate. The product, which initially is developed for long term treatment of prostate cancer, is based on Camurus' proprietary FluidCrystal® injection depot technology and have been designed for simple and convenient administration, also by patients themselves, by a prefilled syringe with a thin needle and a needle stick protection device.

CAM2032 is developed for self-administration, which has the potential to increase flexibility for patients concurrently with reducing the burden of scheduling injections. The development of an auto-injector version is expected to further simplify handling and administration of CAM2032. Thanks to the product’s user-friendly design, CAM2032 does not require reconstitution or being kept at a special temperature prior to administration in a small-volume (0.2 or 0.4 mL) liquid with a thin 27 gauge needle. After injection, the lipid formulation is transformed into a liquid crystal gel matrix which slowly releases therapeutic levels of leuprolide over at least a month.

Compared with other injectable GnRH agonist products on the market, CAM2032 has several potential advantages, including its simple administration, small injection volume, thin needle and the possibility of self-administration by patients.

CAM2032 key properties

  • Ready-to-use product design
  • Prefilled syringe adapted for self-administration
  • Thin needle and small injection volume
  • Compatible with autoinjectors
  • Manufacturing by standard processes




episil® oral liquid

episil® oral liquid

episil® oral liquid

episil® oral liquid is a lipid-based fluid developed for the management and relief of pain associated with oral lesions of various aetiologies such as oral mucositis, a painful side effect of cancer therapies. After administration, and in contact with small quantities of saliva present in the oral cavity, the lipid mixture self-assembles to form a robust protective lipid membrane that strongly adheres to the oral mucosa, and soothes painful ulcerations.

episil® oral liquid is based on Camurus’ FluidCrystal® topical bioadhesive technology, and has been clinically proven to provide effective and rapid oral pain relief that lasts for up to 8 hours. episil® liquid helps patients to maintain their quality of life while undergoing cancer treatment.

For more information, see www.episil.net


UP

Important information

The information contained in this section of Camurus AB’s (the "Company") website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Canada, Japan, Australia, New Zealand, South Africa, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Canada, Japan, Australia, New Zealand, South Africa, Hong Kong, Singapore or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction. Any securities of the Company referred to on this website (the "Securities") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Securities have also not been and will also not be registered under the applicable securities laws of Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in, Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore. There will be no public offer of the Shares in Canada, Japan, Australia, New Zealand, South Africa, Hong Kong or Singapore. Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person